Nervous Disorder TRIZ Cases

Asiaticoside and madecassoside inhibit serotonin reuptake while minimizing side effects through Centella asiatica extraction.

Subanesthetic NMDA receptor antagonists decrease synapse numbers, alleviating social interaction deficits associated with Smith-Magenis Syndrome.

AAV-delivered AADC polynucleotides provide long-term gene expression to stabilize motor symptoms and reduce side effects from systemic dopamine replacement.

Akkermansia muciniphila fragments restore gut barrier function, reducing inflammation to treat obesity-related metabolic dysfunctions.

Aromatic azole compounds inhibit calcium influx via SOCE channels, avoiding adverse effects on cell survival and proliferation.

Vapor-phase decarboxylation of cannabis extracts minimizes thermal degradation and oxidation, preserving active cannabinoids and terpenes.

Next-generation sequencing tracks clone enrichment to identify specific antibodies, overcoming high background signals in vivo.

Segmented dried blood spot sampling with internal standards simplifies complex drug level verification for pregnant subjects.

Specific Lactobacillus and Bifidobacterium strains modulate the gut-brain axis to reduce depression, anxiety, and cravings during smoking cessation.

A modified anti-human transferrin receptor antibody penetrates the blood-brain barrier via transcytosis pathways.

Intraarterial catheter delivers hyperosmolar agents under MRI guidance to open the blood-brain barrier at specific brain locations.

Culturing peripheral blood monocytes with interleukin-34 and granulocyte-macrophage colony stimulating factor produces functional microglial cells.

64Zn-enriched zinc complexes enhance phagocytic activity to reduce inflammatory shifts and limit neuronal destruction in Parkinson's disease.

Young donor blood plasma fractions reverse age-related cognitive decline by restoring molecular integrity, overcoming limited success of current therapies.

A multiparticulate granule formulation uses sodium bicarbonate to generate carbon dioxide gas within the stomach.

Inhibitory nucleic acid molecules suppress PTB protein expression to convert astrocytes into functional neurons.

Formula I compounds stabilize protein conformation to prevent misfolding and inhibit toxic amyloid structure formation.

Continuous subcutaneous exenatide delivery avoids gastric emptying delays, allowing stable oral medication absorption.

Modified oligonucleotide ISIS 443139 targets HTT RNA to reduce mutant protein levels in the central nervous system.

Gadolinium-labeled VHH antibodies cross the blood-brain barrier to image amyloid plaques without radioactive isotopes.

Brain targeting peptide covalently couples with antibodies to traverse the blood brain barrier via receptor mediated transcytosis.

Temporary amide linkages enable autohydrolysis of carrier-linked prodrugs, releasing active entities without toxic intermediates.

Maleimide compounds inhibit DIO3 via stable selenium adducts, increasing brain T3 to treat depression while sparing heart and bone tissue.

Controls polymorphic form predictability through specific solvent systems, ensuring consistent therapeutic effectiveness.

Modified placental tissue delivers pro-angiogenic factors to induce blood vessel formation in non-cardiovascular regions.

Vinylarene derivatives inhibit IDO-1 enzyme activity to address the lack of approved treatments for cancer and autoimmune diseases.

Protein biomarker panels detect acquired central nervous system injuries through quantitative concentration analysis.

Extracting neural stem cells from amniotic fluid eliminates donor variability and ethical concerns while enabling long-term expansion.

Transdermal tilivapram administration modulates theta power and gamma-band phase locking to improve processing speed in neuropsychiatric patients.

Segmented PLGA injections target multiple receptor sites locally to reduce systemic side effects in diabetic peripheral neuropathy.

Humanized anti-TDP-43 antibodies bind pathological protein aggregates and physiological forms to enable targeted therapeutic intervention.

Small molecule peptidomimetics mimic cadherin recognition sequences to modulate cell adhesion and migration.

Segmented cortical and striatal uptake patterns stage beta amyloid pathology, resolving inconclusive diagnostic results from global assessments.

Specific urea derivatives inhibit ASK1 to treat fibrotic diseases while reducing off-target effects via parameter changes.

Chimeric antigen receptor-engineered T regulatory cells inhibit neuroinflammation and slow disease progression by targeting pathological proteins.

A movable sheath controls needle exposure to prevent accidental punctures of non-target tissues during minimally invasive procedures.

Parenteral followed by enteral deproteinised calf blood preparation reduces Total Symptom Score while avoiding central nervous system side effects.

Vasopressin analogs induce aquaporin-4 water channels to enhance brain waste clearance, addressing neurocognitive disorders by removing toxic proteins.

Co-administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime with antipsychotics prevents weight gain and metabolic disorders.

Enantiopure haptens conjugated to carrier proteins elicit high-affinity antibodies targeting (-)-nicotine, resolving racemic vaccine limitations.

Low-dose fenfluramine administration reduces seizure frequency and improves breathing in Rett syndrome patients.

Aromatic-cationic peptides reduce endothelial swelling and infarct size during ischemia-reperfusion injury.

Antibodies targeting Kv1.3 extracellular loops resolve specificity issues by blocking ion conductance for autoimmune treatment.

Amide-linked Trolox derivatives address inadequate mitochondrial treatments by enhancing energy biomarkers and reducing disorder symptoms.

PDE1 inhibitors modulate cAMP and cGMP levels to overcome myelin inhibition and reduce inflammatory responses during axonal regeneration.

An acrylate-rubber hybrid adhesive matrix enhances donepezil skin penetration rates in transdermal drug delivery systems.

Zscan4 expression promotes telomere recombination to maintain genomic integrity during long-term proliferation.